Beijing Varnotech Biopharm Ltd, a China-based specialist in human vaccines, has successfully raised RMB 600 million (approximately USD 83 million) in a Series B financing round. The round was co-led by the Beijing Medical and Health Industry Investment Fund and Huayin Financial Investment, with additional contributions from Watere Capital, Beijing Shunxi Equity Investment Fund, 3E Bioventures Capital, and others.
The funds will be allocated to clinical studies for Varnotech’s herpes zoster vaccine, influenza vaccine, and other candidates in its pipeline, as well as the construction of manufacturing facilities for vaccines and adjuvants. Varnotech is advancing several preventative vaccines, with both the herpes zoster and influenza vaccines currently in clinical development.- Flcube.com
